text: Imaging Evaluation of Pulmonary and Non Ischaemic Cardiovascular Manifestations of COVID 19 Coronavirus Disease 2019 COVID 19 has been a pandemic challenge for the last year Cardiovascular disease is the most described comorbidity in COVID 19 patients and it is related to the disease severity and progression COVID 19 induces direct damage on cardiovascular system leading to arrhythmias and myocarditis and indirect damage due to endothelial dysfunction and systemic inflammation with a high inflammatory burden Indirect damage leads to myocarditis coagulation abnormalities and venous thromboembolism Takotsubo cardiomyopathy Kawasaki like disease and multisystem inflammatory syndrome in children Imaging can support the management assessment and prognostic evaluation of these patients Ultrasound is the most reliable and easy to use in emergency setting and in the ICU as a first approach The focused approach is useful in management of these patients due its ability to obtain quick and focused results This tool is useful to evaluate cardiovascular disease and its interplay with lungs However a detailed echocardiography evaluation is necessary in a complete assessment of cardiovascular involvement Computerized tomography is highly sensitive but it might not always be available Cardiovascular magnetic resonance and nuclear imaging may be helpful to evaluate COVID 19 related myocardial injury but further studies are needed This review deals with different modalities of imaging evaluation in the management of cardiovascular non ischaemic manifestations of COVID 19 comparing their use in emergency and in intensive care 